The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
VJVirtual | POLE mutations as predictive biomarkers for immunotherapy in GI cancers
Umair Mahmood, BSc, MSc, University College London Hospital, London, UK, discusses the potential of POLE mutations as predictive biomarkers for immune checkpoint inhibitor therapy in gastrointestinal cancers. In a study, patients with colorectal or gallbladder cancer harboring POLE mutations experienced durable responses to immunotherapy despite differing microsatellite stability and tumor mutational burden profiles. These hypothesis-generating findings suggest POLE alterations may help identify patients likely to benefit from immune checkpoint inhibitors and support prospective studies to validate their clinical utility. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
